Focused On-demand Library for PCI domain-containing protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5JVF3

UPID:

PCID2_HUMAN

Alternative names:

CSN12-like protein

Alternative UPACC:

Q5JVF3; A6NK09; Q3ZCX1; Q5TC57; Q5TC58; Q9H7K1; Q9HBZ7; Q9NUK6; Q9NVY1; Q9NW44; Q9NWH3

Background:

PCI domain-containing protein 2, also known as CSN12-like protein, plays a crucial role in B-cell survival by regulating the expression of MAD2L1 during B cell differentiation. It is a part of the TREX-2 complex, facilitating mRNA export to the cytoplasm. This protein binds and stabilizes BRCA2, controlling R-loop-associated DNA damage and transcription-associated genomic instability. Additionally, it interacts with ZNHIT1 to block the SRCAP chromatin remodeling complex, influencing lymphoid lineage commitment by suppressing key regulator genes.

Therapeutic significance:

Understanding the role of PCI domain-containing protein 2 could open doors to potential therapeutic strategies, particularly in enhancing B-cell survival and managing transcription-associated genomic instability.